UK markets closed

GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
20.75+0.86 (+4.32%)
As of 12:43PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close19.89
Open20.80
Bid0.00 x 0
Ask0.00 x 0
Day's range20.18 - 20.80
52-week range16.50 - 21.54
Volume599
Avg. volume58,761
Market cap106.789B
Beta (5Y monthly)0.40
PE ratio (TTM)18.25
EPS (TTM)1.14
Earnings dateN/A
Forward dividend & yield1.09 (5.49%)
Ex-dividend date18 Nov 2021
1y target estN/A
  • Motley Fool

    Why Vir Biotechnology Stock Is Soaring Today

    Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.

  • Motley Fool

    Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb

    In particular, GlaxoSmithKline (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY) are two of the world's most preeminent pharmaceutical companies, but neither has consistently outperformed the market over the past five years. Right now, Bristol-Myers is in the doldrums. Over the past three years, its quarterly revenue has jumped 94.6% and quarterly net income has risen 33.3%.

  • Zacks

    Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

    Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.